



Final Appraisal Recommendation

Advice No: 2916 – October 2016

**Eltrombopag (Revolade®) 25 mg, 50 mg film coated tablets
and 25 mg powder for oral suspension**

Limited submission by Novartis Pharmaceuticals UK Ltd

Recommendation of AWMSG

Eltrombopag (Revolade®) is recommended as an option for use within NHS Wales for the treatment of patients aged 1 year to < 18 years with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).

This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.

Additional note(s):

- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2692), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Novartis Pharmaceuticals UK Ltd
Date of first issue	October 2016
Last reviewed	August 2020

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2916:
Eltrombopag (Revolade®) 25 mg, 50 mg film coated tablets and 25 mg powder for oral suspension.
October 2016.